John P. Saharek
2022
In 2022, John P. Saharek earned a total compensation of $656.9K as Chief Commercial Officer and President, ImprimisRx at Imprimis Pharmaceuticals, a 75% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $261,287 |
|---|---|
| Salary | $378,955 |
| Other | $16,645 |
| Total | $656,887 |
Saharek received $379K in salary, accounting for 58% of the total pay in 2022.
Saharek also received $261.3K in non-equity incentive plan and $16.6K in other compensation.
Rankings
In 2022, John P. Saharek's compensation ranked 3,885th out of 5,717 executives tracked by ExecPay. In other words, Saharek earned more than 32.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,885 out of 5,717 | 32nd |
Division Manufacturing | 2,195 out of 3,111 | 29th |
Major group Chemicals And Allied Products | 1,058 out of 1,410 | 25th |
Industry group Drugs | 992 out of 1,311 | 24th |
Industry Pharmaceutical Preparations | 724 out of 957 | 24th |
Source: SEC filing on April 28, 2023.
Saharek's colleagues
We found two more compensation records of executives who worked with John P. Saharek at Imprimis Pharmaceuticals in 2022.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019